The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. doi:10.3969/j.issn.1001-5256.2022.02.009
   Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109–1113. doi:10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Barrera-Saldana HA, Fernandez-Garza LE, Barrera-Barrera SA. Liquid biopsy in chronic liver disease. Ann Hepatol. 2021;20:100197. doi:10.1016/j.aohep.2020.03.008
   PubMed Web of Science ®Google Scholar
• Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med. 2021;145(6):678–686. doi:10.5858/arpa.2019-0559-RA
   PubMed Web of Science ®Google Scholar
• Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157(1):54–64. doi:10.1053/j.gastro.2019.02.049
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers. 2012;32(4):265–271. doi:10.3233/DMA-2011-0878
   PubMed Web of Science ®Google Scholar
• Chen S, Chen H, Gao S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res. 2017;47(4):312–320. doi:10.1111/hepr.12739
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Xu F, Zhang L, He W, et al. The diagnostic value of serum PIVKA-II alone or in combination with AFP in Chinese hepatocellular carcinoma patients. Dis Markers. 2021;2021:8868370. doi:10.1155/2021/8868370
   PubMed Web of Science ®Google Scholar
• Durin L, Pradines A, Basset C, et al. Liquid biopsy of non-plasma body fluids in non-small cell lung cancer: look closer to the tumor! Cells. 2020;9(11). doi:10.3390/cells9112486
   PubMed Web of Science ®Google Scholar
• Mader S, Pantel K. Liquid biopsy: current status and future perspectives. Oncol Res Treat. 2017;40(7–8):404–408. doi:10.1159/000478018
   PubMed Web of Science ®Google Scholar
• Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018;10:1758835918794630. doi:10.1177/1758835918794630
   Web of Science ®Google Scholar
• Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142(3–4):241–243.
   PubMedGoogle Scholar
• Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10:466. doi:10.1126/scitranslmed.aat4921
   Web of Science ®Google Scholar
• Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162. doi:10.1371/journal.pgen.1006162
   PubMed Web of Science ®Google Scholar
• Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7(30):48832–48841. doi:10.18632/oncotarget.9453
   PubMedGoogle Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094
   PubMed Web of Science ®Google Scholar
• Mehes G. Liquid biopsy for predictive mutational profiling of solid cancer: the pathologist’s perspective. J Biotechnol. 2019;297:66–70. doi:10.1016/j.jbiotec.2019.04.002
   PubMed Web of Science ®Google Scholar
• Lenaerts L, Tuveri S, Jatsenko T, et al. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope? Acta Clin Belg. 2020;75(1):9–18. doi:10.1080/17843286.2019.1671653
   PubMed Web of Science ®Google Scholar
• Nishida N. Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis. Histol Histopathol. 2010;25(5):647–654. doi:10.14670/HH-25.647
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161. doi:10.1038/nmat4997
   PubMed Web of Science ®Google Scholar
• Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci. 2020;16(9):1551–1562. doi:10.7150/ijbs.44024
   PubMed Web of Science ®Google Scholar
• Lu CY, Chen SY, Peng HL, et al. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget. 2017;8(4):6406–6418. doi:10.18632/oncotarget.14115
   PubMedGoogle Scholar
• Araujo OC, Rosa AS, Fernandes A, et al. RASSF1A and DOK1 promoter methylation levels in hepatocellular carcinoma, cirrhotic and non-cirrhotic liver, and correlation with liver cancer in Brazilian patients. PLoS One. 2016;11(4):e0153796. doi:10.1371/journal.pone.0153796
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Huang Y, Wei L, et al. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection. Neoplasma. 2017;64(5):795–802. doi:10.4149/neo_2017_519
   PubMed Web of Science ®Google Scholar
• Hlady RA, Sathyanarayan A, Thompson JJ, et al. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma. Hepatology. 2019;69(2):639–652. doi:10.1002/hep.30211
   PubMed Web of Science ®Google Scholar
• Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–2205. doi:10.1136/gutjnl-2019-318882
   PubMed Web of Science ®Google Scholar
• Gu DL, Chen YH, Shih JH, et al. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma. World J Gastroenterol. 2013;19(47):8873–8879. doi:10.3748/wjg.v19.i47.8873
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–39 e4. doi:10.1053/j.gastro.2015.05.061
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang X, Zhou SL, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer. 2016;7(13):1907–1914. doi:10.7150/jca.15823
   PubMed Web of Science ®Google Scholar
• Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol. 2020;146(7):1625–1645. doi:10.1007/s00432-020-03219-5
   PubMed Web of Science ®Google Scholar
• von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2021;40(1):140–151. doi:10.1038/s41388-020-01519-1
   PubMed Web of Science ®Google Scholar
• Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16(1):149. doi:10.1186/s12943-017-0712-x
   PubMed Web of Science ®Google Scholar
• Bell RJ, Rube HT, Xavier-Magalhaes A, et al. Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res. 2016;14(4):315–323. doi:10.1158/1541-7786.MCR-16-0003
   PubMed Web of Science ®Google Scholar
• Bassaganyas L, Pinyol R, Esteban-Fabro R, et al. Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma. Clin Cancer Res. 2020;26(23):6350–6361. doi:10.1158/1078-0432.CCR-20-1497
   PubMed Web of Science ®Google Scholar
• Xu H, Zhu X, Xu Z, et al. Non-invasive analysis of genomic copy number variation in patients with hepatocellular carcinoma by next generation DNA sequencing. J Cancer. 2015;6(3):247–253. doi:10.7150/jca.10747
   PubMed Web of Science ®Google Scholar
• Duan M, Hao J, Cui S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018;28(3):359–373. doi:10.1038/cr.2018.11
   PubMed Web of Science ®Google Scholar
• Oh CR, Kong SY, Im HS, et al. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer. 2019;19(1):292. doi:10.1186/s12885-019-5483-x
   PubMed Web of Science ®Google Scholar
• Oellerich M, Schutz E, Beck J, et al. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017;54(3):205–218. doi:10.1080/10408363.2017.1299683
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Z, Ji K, et al. Clinical application value of circulating cell-free DNA in hepatocellular carcinoma. Front Mol Biosci. 2021;8:736330. doi:10.3389/fmolb.2021.736330
   PubMed Web of Science ®Google Scholar
• Chen VL, Xu D, Wicha MS, et al. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol. 2020;18(13):2879–902 e9. doi:10.1016/j.cgh.2020.04.019
   PubMed Web of Science ®Google Scholar
• Yan L, Chen Y, Zhou J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis. 2018;67:92–97. doi:10.1016/j.ijid.2017.12.002
   PubMed Web of Science ®Google Scholar
• Qu C, Wang Y, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019;116(13):6308–6312. doi:10.1073/pnas.1819799116
   PubMed Web of Science ®Google Scholar
• Yeo W, Wong N, Wong WL, et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005;25(2):266–272. doi:10.1111/j.1478-3231.2005.01084.x
   PubMed Web of Science ®Google Scholar
• Cai Z, Chen G, Zeng Y, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma. Clin Cancer Res. 2019;25(17):5284–5294. doi:10.1158/1078-0432.CCR-18-3477
   PubMed Web of Science ®Google Scholar
• Chen L, Abou-Alfa GK, Zheng B, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res. 2021;31(5):589–592. doi:10.1038/s41422-020-00457-7
   PubMed Web of Science ®Google Scholar
• Ono A, Fujimoto A, Yamamoto Y, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol. 2015;1(5):516–534. doi:10.1016/j.jcmgh.2015.06.009
   PubMedGoogle Scholar
• Wang D, Xu Y, Goldstein JB, et al. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int. 2020;40(8):1997–2007. doi:10.1111/liv.14463
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421. doi:10.1155/2010/617421
   PubMedGoogle Scholar
• Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436. doi:10.1002/hep.31165
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–166. doi:10.1016/j.ccr.2008.01.013
   PubMed Web of Science ®Google Scholar
• Liu S, Li N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144(5):1031–41e10. doi:10.1053/j.gastro.2013.01.046
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10573–10583. doi:10.3748/wjg.v21.i37.10573
   PubMed Web of Science ®Google Scholar
• Espejo-Cruz ML, Gonzalez-Rubio S, Zamora-Olaya J, et al. Circulating tumor cells in hepatocellular carcinoma: a comprehensive review and critical appraisal. Int J Mol Sci. 2021;22(23). doi:10.3390/ijms222313073
   PubMed Web of Science ®Google Scholar
• Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280–281. doi:10.1016/j.jhep.2009.10.026
   PubMed Web of Science ®Google Scholar
• Kelley RK, Magbanua MJ, Butler TM, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206. doi:10.1186/s12885-015-1195-z
   PubMed Web of Science ®Google Scholar
• Cheng Y, Luo L, Zhang J, et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma. J Gastrointest Surg. 2019;23(12):2354–2361. doi:10.1007/s11605-018-04067-y
   PubMed Web of Science ®Google Scholar
• Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114. doi:10.1186/s12943-019-1043-x
   PubMed Web of Science ®Google Scholar
• Liu HY, Qian HH, Zhang XF, et al. Improved method increases sensitivity for circulating hepatocellular carcinoma cells. World J Gastroenterol. 2015;21(10):2918–2925. doi:10.3748/wjg.v21.i10.2918
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X, Zhang J, et al. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. Cancer Biol Ther. 2016;17(11):1177–1187. doi:10.1080/15384047.2016.1235665
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang C, Wang G, et al. Aptamer-mediated transparent-biocompatible nanostructured surfaces for hepatocellular circulating tumor cells enrichment. Theranostics. 2016;6(11):1877–1886. doi:10.7150/thno.15284
   PubMed Web of Science ®Google Scholar
• Guo W, Sun YF, Shen MN, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018;24(9):2203–2213. doi:10.1158/1078-0432.CCR-17-1753
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang B, Wu J, et al. Association of preoperative EpCAM circulating tumor cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer. 2016;16:506. doi:10.1186/s12885-016-2526-4
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo L, Cheng Y, et al. Correlation between postoperative early recurrence of hepatocellular carcinoma and mesenchymal circulating tumor cells in peripheral blood. J Gastrointest Surg. 2018;22(4):633–639. doi:10.1007/s11605-017-3619-3
   PubMed Web of Science ®Google Scholar
• Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78(16):4731–4744. doi:10.1158/0008-5472.CAN-17-2459
   PubMed Web of Science ®Google Scholar
• Zhang Q, Rong Y, Yi K, et al. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–12071. doi:10.7150/thno.48918
   PubMed Web of Science ®Google Scholar
• Sukowati CHC, Cabral LKD, Tiribelli C, et al. Circulating long and circular noncoding RNA as non-invasive diagnostic tools of hepatocellular carcinoma. Biomedicines. 2021;9(1). doi:10.3390/biomedicines9010090
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Masaki T. Molecular and functional roles of MicroRNAs in the progression of hepatocellular carcinoma-a review. Int J Mol Sci. 2020;21:21. doi:10.3390/ijms21218362
   Web of Science ®Google Scholar
• Wei J, Feng L, Li Z, et al. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother. 2013;67(5):387–392. doi:10.1016/j.biopha.2013.03.014
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhou JK, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77. doi:10.1186/s12943-020-01188-4
   PubMed Web of Science ®Google Scholar
• Soda N, Rehm BHA, Sonar P, et al. Advanced liquid biopsy technologies for circulating biomarker detection. J Mater Chem B. 2019;7(43):6670–6704. doi:10.1039/c9tb01490j
   PubMed Web of Science ®Google Scholar
• Hung CH, Hu TH, Lu SN, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer. 2016;138(3):714–720. doi:10.1002/ijc.29802
   PubMed Web of Science ®Google Scholar
• Tsai YS, Huang CI, Tsai PC, et al. Circulating Let-7 family members as non-invasive biomarkers for predicting hepatocellular carcinoma risk after antiviral treatment among chronic Hepatitis C patients. Cancers. 2022;14(8). doi:10.3390/cancers14082023
   Web of Science ®Google Scholar
• Zekri AN, Youssef AS, El-Desouky ED, et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol. 2016;37(9):12273–12286. doi:10.1007/s13277-016-5097-8
   PubMedGoogle Scholar
• Loosen SH, Castoldi M, Jordens MS, et al. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC. PLoS One. 2021;16(3):e0247917. doi:10.1371/journal.pone.0247917
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–4788. doi:10.1200/JCO.2011.38.2697
   PubMed Web of Science ®Google Scholar
• Yu F, Lu Z, Chen B, et al. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagn Pathol. 2015;10:129. doi:10.1186/s13000-015-0369-y
   PubMed Web of Science ®Google Scholar
• Xie Y, Yao Q, Butt AM, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014;15(9):1248–1255. doi:10.4161/cbt.29688
   PubMed Web of Science ®Google Scholar
• Wu C, Wang X, Zhang J, et al. MicroRNA-224 expression and polymorphism predict the prognosis of Hepatitis B virus-related hepatocellular carcinoma patients after liver resection. Clin Lab. 2019;65(6). doi:10.7754/Clin.Lab.2018.181025
   Web of Science ®Google Scholar
• Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804–815. doi:10.1016/S1470-2045(15)00048-0
   PubMed Web of Science ®Google Scholar
• Jin Y, Wong YS, Goh BKP, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep. 2019;9(1):10464. doi:10.1038/s41598-019-46872-8
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng Y, Xiao X, et al. A circulating long noncoding RNA panel serves as a diagnostic marker for hepatocellular carcinoma. Dis Markers. 2020;2020:5417598. doi:10.1155/2020/5417598
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou Y, Yang G, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta. 2019;492:37–44. doi:10.1016/j.cca.2019.02.001
   PubMed Web of Science ®Google Scholar
• Zhu K, Zhan H, Peng Y, et al. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis. 2020;41(3):296–302. doi:10.1093/carcin/bgz154
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:6478. doi:10.1126/science.aau6977
   Web of Science ®Google Scholar
• Chen W, Mao Y, Liu C, et al. Exosome in Hepatocellular Carcinoma: an update. J Cancer. 2021;12(9):2526–2536. doi:10.7150/jca.54566
   PubMed Web of Science ®Google Scholar
• He R, Wang Z, Shi W, et al. Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. Biomed Pharmacother. 2021;138:111529. doi:10.1016/j.biopha.2021.111529
   PubMed Web of Science ®Google Scholar
• Nabet BY, Qiu Y, Shabason JE, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 2017;170(2):352–66 e13. doi:10.1016/j.cell.2017.06.031
   PubMed Web of Science ®Google Scholar
• Conigliaro A, Costa V, Lo Dico A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:155. doi:10.1186/s12943-015-0426-x
   PubMed Web of Science ®Google Scholar
• Marzan AL, Nedeva C, Mathivanan S. Extracellular vesicles in metabolism and metabolic diseases. Subcell Biochem. 2021;97:393–410. doi:10.1007/978-3-030-67171-6_15
   PubMedGoogle Scholar
• Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic landscape of liquid biopsy for hepatocellular carcinoma personalized medicine. Cancer Genomics Proteomics. 2021;18(3 Suppl):369–383. doi:10.21873/cgp.20266
   PubMed Web of Science ®Google Scholar
• Chitti SV, Nedeva C. Extracellular vesicles contain putative cancer biomarkers. Subcell Biochem. 2021;97:363–374. doi:10.1007/978-3-030-67171-6_13
   PubMedGoogle Scholar
• Suwatthanarak T, Thiodorus IA, Tanaka M, et al. Microfluidic-based capture and release of cancer-derived exosomes via peptide-nanowire hybrid interface. Lab Chip. 2021;21(3):597–607. doi:10.1039/d0lc00899k
   PubMed Web of Science ®Google Scholar
• Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66(4):1125–1143. doi:10.1002/hep.29291
   PubMed Web of Science ®Google Scholar
• Tseng HH, Chang JG, Hwang YH, et al. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol. 2009;135(10):1413–1420. doi:10.1007/s00432-009-0585-5
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kohgo Y, Ohtake T. Splicing variant of hepcidin mRNA. Vitam Horm. 2019;110:131–141. doi:10.1016/bs.vh.2019.01.006
   PubMed Web of Science ®Google Scholar
• Wang X, Shen H, Zhangyuan G, et al. 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 2018;9(2):159. doi:10.1038/s41419-017-0180-7
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12(1):133. doi:10.1186/s13045-019-0806-6
   PubMed Web of Science ®Google Scholar
• Wang H, Hou L, Li A, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014;2014:864894. doi:10.1155/2014/864894
   PubMed Web of Science ®Google Scholar
• Wang W, Li H, Zhou Y, et al. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma. Cancer Biomark. 2013;13(5):351–357. doi:10.3233/CBM-130370
   PubMed Web of Science ®Google Scholar
• Li W, Xue H, Li Y, et al. HIPK3 circular RNA promotes metastases of HCC through sponging miR-338-3p to induce ZEB2 expression. Dig Dis Sci. 2021;66(10):3439–3447. doi:10.1007/s10620-020-06688-3
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Liu Y, et al. Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for hepatocellular carcinoma. Med Sci Monit. 2015;21:1864–1871. doi:10.12659/MSM.893082
   PubMed Web of Science ®Google Scholar
• Xue X, Wang X, Zhao Y, et al. Exosomal miR-93 promotes proliferation and invasion in hepatocellular carcinoma by directly inhibiting TIMP2/TP53INP1/CDKN1A. Biochem Biophys Res Commun. 2018;502(4):515–521. doi:10.1016/j.bbrc.2018.05.208
   PubMed Web of Science ®Google Scholar
• Sun L, Su Y, Liu X, et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J Cancer. 2018;9(15):2631–2639. doi:10.7150/jca.24978
   PubMed Web of Science ®Google Scholar
• Xu H, Chen Y, Dong X, et al. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27(6):710–716. doi:10.1158/1055-9965.EPI-17-0770
   PubMed Web of Science ®Google Scholar
• Lee YR, Kim G, Tak WY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer. 2019;144(6):1444–1452. doi:10.1002/ijc.31931
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen LL, Biogenesis T. Functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442. doi:10.1016/j.molcel.2018.06.034
   PubMed Web of Science ®Google Scholar
• Wang S, Dong Y, Gong A, et al. Exosomal circRNAs as novel cancer biomarkers: challenges and opportunities. Int J Biol Sci. 2021;17(2):562–573. doi:10.7150/ijbs.48782
   PubMed Web of Science ®Google Scholar
• Nahon P, Najean M, Layese R, et al. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Rep. 2022;4(1):100390. doi:10.1016/j.jhepr.2021.100390
   PubMedGoogle Scholar
• An J. Current status and future directions of hepatocellular carcinoma surveillance test based on cost-effective analysis. Korean J Gastroenterol. 2021;78(5):255–260. doi:10.4166/kjg.2021.142
   PubMedGoogle Scholar
• Englmeier F, Bleckmann A, Bruckl W, et al. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. 2022. doi:10.1007/s00432-022-04034-w
   PubMed Web of Science ®Google Scholar
• Izumi D, Zhu Z, Chen Y, et al. Assessment of the diagnostic efficiency of a liquid biopsy assay for early detection of gastric cancer. JAMA Netw Open. 2021;4(8):e2121129. doi:10.1001/jamanetworkopen.2021.21129
   PubMed Web of Science ®Google Scholar
• Wu CF, Lin L, Mao YP, et al. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Med. 2021;19(1):193. doi:10.1186/s12916-021-02076-4
   PubMed Web of Science ®Google Scholar
• van der Poort EKJ, van Ravesteyn NT, van den Broek JJ, et al. The early detection of breast cancer using liquid biopsies: model estimates of the benefits, harms, and costs. Cancers. 2022;14(12). doi:10.3390/cancers14122951
   PubMed Web of Science ®Google Scholar
• Roy D, Lucci A, Ignatiadis M, et al. Cell-free circulating tumor DNA profiling in cancer management. Trends Mol Med. 2021;27(10):1014–1015. doi:10.1016/j.molmed.2021.07.001
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Li T, et al. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer. 2020;44(2):100516. doi:10.1016/j.currproblcancer.2019.100516
   PubMed Web of Science ®Google Scholar
• Prospective suRveillance for very Early hepatoCellular cARcinoma(PreCar) expert panel. [Expert consensus on early screening strategies for liver cancer in China]. Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):515-522. Chinese. doi:10.3760/cma.j.cn501113-20210605-00264
   Google Scholar
• Wu J, Hu S, Zhang L, et al. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics. 2020;10(10):4544–4556. doi:10.7150/thno.40532
   PubMed Web of Science ®Google Scholar
• Huang Z, Hua D, Hu Y, et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res. 2012;18(2):271–276. doi:10.1007/s12253-011-9438-z
   PubMed Web of Science ®Google Scholar
• Wen Y, Han J, Chen J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 2015;137(7):1679–1690. doi:10.1002/ijc.29544
   PubMed Web of Science ®Google Scholar
• El Sharkawi FZ, Awad MS, Elagawy W, et al. Circular RNAs 0064286 and 0000475: potential diagnostic biomarkers in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2021;22(9):3039–3044. doi:10.31557/APJCP.2021.22.9.3039
   PubMedGoogle Scholar
• Guo W, Yang XR, Sun YF, et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014;20(18):4794–4805. doi:10.1158/1078-0432.CCR-14-0251
   PubMed Web of Science ®Google Scholar